Clinical Trials on Cervical in New Zealand

Total 392 results

  • Merck Sharp & Dohme LLC
    Recruiting
    MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
    Uterine Cervical Neoplasms | Stomach Neoplasms | Urinary Bladder Neoplasms | Hepatocellular Carcinoma | Esophageal Neoplasms | Ovarian Neoplasms | Endometrial Neoplasms | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Triple Negative Breast Neoplasms | Gallbladder Neoplasms
    United States, Chile, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Spain, Taiwan, Turkey, Canada
  • Gilead Sciences
    Completed
    Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
    Cervical Cancer | Urinary Bladder Neoplasms | Small Cell Lung Cancer | Hepatocellular Carcinoma | Pancreatic Cancer | Esophageal Cancer | Ovarian Epithelial Cancer | Glioblastoma Multiforme | Gastric Adenocarcinoma | Triple Negative Breast Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Renal Cell Cancer and other conditions
    United States
  • Advenchen Laboratories, LLC
    Active, not recruiting
    Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002) (AL3818)
    Fallopian Tube Carcinoma | Cervical Carcinoma | Endometrial Carcinoma | Ovarian Carcinoma | Primary Peritoneal Carcinoma
    Korea, Republic of, Spain, United States, United Kingdom, China, Italy
  • OncoC4, Inc.
    National Cancer Institute (NCI)
    Recruiting
    Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC (PRESERVE-001)
    Cervical Cancer | Small Cell Lung Cancer | Adenoid Cystic Carcinoma | Metastatic Renal Cell Carcinoma | Metastatic Colorectal Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Metastatic Melanoma | Pancreas Cancer | Metastatic... and other conditions
    United States, Australia
  • BioAtla, Inc.
    Recruiting
    A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors
    Melanoma | Carcinoma | Renal Cell Carcinoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | NSCLC | Cervical Carcinoma | Urothelial Carcinoma | Solid Tumor, Adult
    United States, Australia
  • Xencor, Inc.
    ICON plc
    Completed
    A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors (DUET-2)
    Melanoma | Renal Cell Carcinoma | Cervical Cancer | Nasopharyngeal Carcinoma | Small Cell Lung Carcinoma | Hepatocellular Carcinoma | Thymic Carcinoma | Thymoma | Non-small Cell Lung Carcinoma | Mesothelioma | Squamous Cell Carcinoma of the Head and Neck | Cholangiocarcinoma | Breast Carcinoma | Fallopian Tube Carcinoma and other conditions
    United States
  • OncoC4, Inc.
    Avance Clinical; OncoC4 AU Pty Ltd
    Recruiting
    Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors (PRESERVE-009)
    Melanoma | Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Fallopian Tube Cancer | Non Small Cell Lung Cancer | Bile Duct Cancer | Bladder Cancer | Endometrial Cancer | Head and Neck Squamous Cell Carcinoma | Anal Cancer | Primary Peritoneal... and other conditions
    Australia
  • Corvus Pharmaceuticals, Inc.
    Completed
    CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
    Sarcoma | Cervical Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck | Bladder Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Renal Cell Cancer | Non-hodgkin Lymphoma | Metastatic Castration Resistant Prostate...
    United States, Australia
  • Merck Sharp & Dohme LLC
    Recruiting
    Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
    Cervical Cancer | Small Cell Lung Carcinoma | Neuroendocrine Tumor | Advanced Solid Tumors | Mesothelioma | Vulvar Cancer | Cholangiocarcinoma | Bile Duct Cancer | Endometrial Cancer | Advanced Cancer | Cervical Carcinoma | Endometrial Carcinoma | Thyroid Carcinoma | Thyroid Cancer | Anal Cancer | Colorectal Carcinoma | Carcinoid... and other conditions
    Canada, France, Germany, Italy, Mexico, Netherlands, Poland, Russian Federation, Taiwan, United States, Brazil, Colombia, Israel, Korea, Republic of, Norway, Philippines, South Africa, Spain, Australia, Denmark, Chile, Portugal, Peru
  • Eli Lilly and Company
    Loxo Oncology, Inc.
    Recruiting
    A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
    Cervical Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Renal Pelvis Cancer | Urinary Bladder Neoplasm | Recurrent...
    United States
  • Fate Therapeutics
    Terminated
    Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
    Melanoma | Lymphoma | Renal Cell Carcinoma | Cervical Cancer | Head and Neck Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | NSCLC | Advanced Solid Tumor | Small-cell Lung Cancer | HER2-positive Breast Cancer | Pancreas Cancer | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability and other conditions
    United States
  • Totus Medicines
    Recruiting
    A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With Select Solid Tumors
    Cervical Cancer | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Squamous Cell Carcinoma of Head and Neck | Endometrial Cancer | Non-small Cell Lung Cancer | Urothelial Carcinoma | HER2-negative Breast Cancer
    United States
  • Fate Therapeutics
    Completed
    FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
    Melanoma | Lymphoma | Renal Cell Carcinoma | Cervical Cancer | Head and Neck Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | NSCLC | Advanced Solid Tumors | HER2-positive Breast Cancer | Pancreas Cancer | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability and other conditions
    United States
  • AstraZeneca
    Active, not recruiting
    Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
    Cervical Cancer | Ovarian Cancer | Pharmacokinetics | Endometrial Cancer | Pharmacodynamics | Safety and Tolerability | Advanced Solid Malignancy | Tumour Response | Advanced or Metastatic Breast Cancer | PIK3CA | AKT1 | PTEN | ER Positive | HER2 Positive
    United States, Italy, Canada, France, Japan, United Kingdom, Spain, Netherlands, Denmark, Singapore
  • Incyte Corporation
    Completed
    A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
    Melanoma | Renal Cell Carcinoma | Cervical Cancer | Stomach Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | NSCLC | Mesothelioma | Squamous Cell Carcinoma of the Head and Neck | Non-small Cell Lung Cancer | Gastroesophageal Junction Cancer | Urothelial... and other conditions
    United States
  • Genmab
    BioNTech SE
    Active, not recruiting
    GEN1046 Safety Trial in Patients With Malignant Solid Tumors
    Cervical Cancer | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Solid Tumors | Endometrial Carcinoma | Urothelial Carcinoma
    United States, Spain, Israel, Czechia, Georgia, Italy, Poland, Turkey, Hungary, Ukraine
  • Exelixis
    Recruiting
    Study of XB002 in Subjects With Solid Tumors (JEWEL-101)
    Cervical Cancer | Pancreatic Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Epithelial Ovarian Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor-positive Breast Cancer | SCCHN | Esophageal SCC | Tissue Factor-Expressing Solid Tumors
    United States, Spain, Australia, Belgium, France, Italy, Netherlands, United Kingdom, Korea, Republic of
  • Mannkind Corporation
    Completed
    Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.
    Melanoma | Small Cell Lung Carcinoma | Gastric Cancer | Mesothelioma | Breast Carcinoma | Cervical Carcinoma | Endometrial Carcinoma | Thyroid Cancer | Liver Cancer | Biliary Tract Cancer | Esophageal Carcinoma | Pancreatic Carcinoma | Gallbladder Cancer | Anal Carcinoma | Testicular Cancer | Neuroendocrine Cancer | Colore... and other conditions
    United States
  • National Cancer Institute (NCI)
    Active, not recruiting
    Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
    Soft Tissue Sarcoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Osteosarcoma | Ewing Sarcoma | Recurrent Renal Cell Carcinoma | Refractory Malignant Solid Neoplasm | Rhabdomyosarcoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Malignant Solid Neoplasm | Recurrent Osteosarcoma | Recurrent... and other conditions
    United States
  • GI Innovation, Inc.
    Merck Sharp & Dohme LLC
    Recruiting
    GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors
    Melanoma | Sarcoma | Renal Cell Carcinoma | Cervical Cancer | Urinary Bladder Cancer | Vulvar Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Vaginal Cancer | Microsatellite Stable...
    Korea, Republic of, United States
  • University of California, San Francisco
    National Institutes of Health (NIH); National Institute on Aging (NIA)
    Active, not recruiting
    4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2 (4RTNI-2)
    Progressive Supranuclear Palsy (PSP) | Corticobasal Degeneration (CBD) | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | Corticobasal Syndrome (CBS) | Cortical-basal Ganglionic Degeneration (CBGD) | Oligosymptomatic/Variant Progressive Supranuclear Palsy (o/vPSP)
    United States, Canada
  • Fusion Pharmaceuticals Inc.
    Recruiting
    A Phase 1/2 Study of [225Ac]-FPI-1434 Injection
    Cervical Cancer | Breast Cancer | Ovarian Cancer | Endometrial Cancer | Uveal Melanoma | Adrenocortical Carcinoma | Advanced Solid Tumours | HER2-negative Breast Cancer | Triple Negative Breast Cancer (TNBC) | Head and Neck Squamous Cell Carcinoma (HNSCC)
    United States, Australia, Canada
  • Rain Oncology Inc
    Terminated
    Milademetan in Advanced/Metastatic Solid Tumors
    Melanoma | Sarcoma | Cervical Cancer | Testicular Germ Cell Tumor | Gastric Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Lung Adenocarcinoma | Solid Tumors | Pancreas Cancer | Head and Neck Carcinoma | Biliary Tract Cancer | Ovarian Carcinoma | Adrenocortical Carcinoma | Bladder Urothelial Carcinoma | Breast... and other conditions
    United States
  • Kymab Limited
    Sanofi
    Active, not recruiting
    Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer
    Melanoma | Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Metastatic Cancer | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Advanced Cancer
    United States, Hungary, Italy, Poland, Taiwan, United Kingdom
  • Incyte Biosciences International Sàrl
    Completed
    A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
    Cervical Cancer | Hepatocellular Carcinoma | Esophageal Cancer | Ovarian Cancer | Mesothelioma | Non-small Cell Lung Cancer (NSCLC) | Urothelial Carcinoma | Merkel Cell Carcinoma | Diffuse Large B-cell Lymphoma | Triple-negative Breast Cancer | Renal Cell Carcinoma (RCC) | Small Cell Lung Cancer (SCLC) | Squamous... and other conditions
    United States
  • Aminex Therapeutics, Inc.
    Recruiting
    Oral AMXT 1501 Dicaprate in Combination With IV DFMO
    Melanoma | Cervical Cancer | Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Solid Tumor | Endometrial Cancer | Advanced Cancer | Diffuse Midline Glioma, H3 K27M-Mutant | Papillary Thyroid Cancer | Solid Carcinoma | Mesotheliomas Pleural | Glioma, Malignant | Ovary Cancer and other conditions
    United States, Australia
  • Arcus Biosciences, Inc.
    Gilead Sciences
    Active, not recruiting
    A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (ARC-12)
    Melanoma | Lymphoma, Non-Hodgkin | Cervical Cancer | Multiple Myeloma | Gastric Cancer | Esophageal Cancer | Advanced Solid Tumor | Gastroesophageal Junction Adenocarcinoma | Non Small Cell Lung Cancer (NSCLC) | Diffuse Large B Cell Lymphoma (DLBCL)
    United States, Spain, Poland
  • Eastern Cooperative Oncology Group
    Recruiting
    Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
    Melanoma | Breast Cancer, NOS | CNS Primary Tumor, NOS | Cervical Cancer, NOS | Colorectal Cancer, NOS | Leukemia, NOS | Lymphoma, NOS | Miscellaneous Neoplasm, NOS | Non-Rhabdomyosarcoma Soft Tissue Sarcoma, NOS | Testicular Nonseminomatous Germ Cell Tumor, NOS | Thyroid Cancer, NOS | Bone Cancer, NOS
    United States
  • Seagen Inc.
    Terminated
    A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
    Cervical Cancer | Ovarian Cancer | Peripheral T-cell Lymphoma | Bladder Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Gastric Carcinoma | Classical Hodgkin Lymphoma | Diffuse Large B-cell Lymphoma | Cutaneous Melanoma | Gastroesophageal Junction...
    United States, Spain, Canada, United Kingdom, France, Italy
  • Adela, Inc
    Recruiting
    cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease (CAMPERR)
    Sarcoma | Lymphoma | Cervical Cancer | Leukemia | Stomach Cancer | Breast Cancer | Head and Neck Cancer | Multiple Myeloma | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Lung Cancer | Prostate Cancer | Brain Cancer | Bladder Cancer | Endometrial Cancer | Thyroid Cancer | Renal Cancer | Hepatobiliary...
    United States
  • Incyte Corporation
    Active, not recruiting
    Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
    Cervical Cancer | Nasopharyngeal Carcinoma | Mesothelioma | Advanced Solid Tumor | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | HepatoCellular Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1)
    France, United States, Japan, Belgium, Australia
  • MacroGenics
    Completed
    A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
    Cervical Cancer | Hematologic Neoplasms | Ovarian Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors | Squamous Cell Carcinoma of Head and Neck | Cholangiocarcinoma | Small-cell Lung Cancer | TNBC - Triple-Negative Breast Cancer | HER2-positive Advanced Solid Tumors
    Hong Kong, United States, Thailand, Australia, Spain, Bulgaria, Poland, Ukraine
  • National Cancer Institute (NCI)
    Recruiting
    Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
    Mucosal Melanoma | Anal Melanoma | Bladder Melanoma | Cervical Melanoma | Esophageal Melanoma | Gallbladder Melanoma | Mucosal Melanoma of the Head and Neck | Mucosal Melanoma of the Urinary System | Oral Cavity Mucosal Melanoma | Penile Mucosal Melanoma | Rectal Melanoma | Recurrent Mucosal Melanoma | Sinonasal... and other conditions
    United States, Canada
  • Klus Pharma Inc.
    Completed
    Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
    Cervical Cancer | Head and Neck Cancer | Mucoepidermoid Carcinoma | Pancreatic Cancer | Recurrent Prostate Cancer | Lung Cancer | Rectal Cancer | Solid Tumor | Prostate Cancer | Cholangiocarcinoma | Bile Duct Cancer | Recurrent Ovarian Carcinoma | Bladder Cancer | Skin Cancer | HER2-positive Breast Cancer | Rare Diseases | Colo-rectal Cancer and other conditions
    United States
  • AstraZeneca
    Recruiting
    Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (PETRA)
    Cervical Cancer | Breast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Bladder Cancer | Endometrial Cancer | Non-small Cell Lung Cancer | Biliary Cancer | Additional Indications Below for Module 4 and 5 | Small Cell Lung Cancer Only in Module 5
    Canada, Spain, China, Korea, Republic of, Italy, Poland, United States, Australia, United Kingdom, Japan, Hungary, Russian Federation, Czechia
  • Nurix Therapeutics, Inc.
    Recruiting
    A Study of NX-1607 in Adults With Advanced Malignancies
    Cervical Cancer | Gastric Cancer | Head and Neck Squamous Cell Carcinoma | Non-small Cell Lung Cancer (NSCLC) | Metastatic Urothelial Carcinoma | Ovarian Cancer, Epithelial | Metastatic Castration-resistant Prostate Cancer (mCRPC) | Triple Negative Breast Cancer (TNBC) | Malignant Pleural Mesothelioma... and other conditions
    United States, United Kingdom
  • Incyte Corporation
    Active, not recruiting
    Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
    Cervical Cancer | Nasopharyngeal Carcinoma | Advanced Solid Tumors | Mesothelioma | Small-cell Lung Cancer | Esophageal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Anal Carcinoma | Cutaneous Squamous Cell Carcinoma | MSI-H/dMMR Tumors | PD-L1 Amplified Tumor (9p24.1) | Urothelial... and other conditions
    Finland, United States, United Kingdom, Belgium, Sweden, Denmark, Norway
  • Xencor, Inc.
    ICON Clinical Research
    Completed
    A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)
    Melanoma | Renal Cell Carcinoma | Nasopharyngeal Carcinoma | Small Cell Lung Carcinoma | Hepatocellular Carcinoma | Fallopian Tube Cancer | Non-small Cell Lung Carcinoma | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Cancer | Epithelial Ovarian Cancer | Intrahepatic Cholangiocarcinoma and other conditions
    United States
  • National Cancer Institute (NCI)
    Active, not recruiting
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
    Glioma | Hematopoietic and Lymphoid Cell Neoplasm | Melanoma | Lymphoma | Multiple Myeloma | Recurrent Ovarian Carcinoma | Breast Carcinoma | Recurrent Head and Neck Carcinoma | Recurrent Lung Carcinoma | Recurrent Skin Carcinoma | Gastric Carcinoma | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory... and other conditions
    United States, Puerto Rico, Guam
  • Xencor, Inc.
    ICON plc
    Active, not recruiting
    A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3)
    Renal Cell Carcinoma | Nasopharyngeal Carcinoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Advanced Solid Tumors | Non-small Cell Lung Carcinoma | Squamous Cell Carcinoma of the Head and Neck | Cervical Carcinoma | Endometrial Carcinoma | Urothelial Carcinoma | Colorectal Carcinoma | Pancreatic Carcinoma and other conditions
    United States
  • National Cancer Institute (NCI)
    Active, not recruiting
    Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
    Malignant Solid Neoplasm | Nasopharyngeal Carcinoma | Adenoid Cystic Carcinoma | Transitional Cell Carcinoma | Cholangiocarcinoma | Intrahepatic Cholangiocarcinoma | Chordoma | Gestational Trophoblastic Tumor | Pseudomyxoma Peritonei | Cervical Adenocarcinoma | Vaginal Adenocarcinoma | Vaginal Squamous Cell... and other conditions
    United States, Guam
  • Medicenna Therapeutics, Inc.
    Merck Sharp & Dohme LLC
    Recruiting
    A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)
    Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions
    United States, Australia, Korea, Republic of, Canada

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe